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ABSTRACT:
Metastatic prostate cancer (PCa) is still an incurable disease. Long non-coding 
RNAs (lncRNAs) may be an overlooked source of cancer biomarkers and therapeutic 
targets. We therefore performed RNA sequencing on paired metastatic/non-
metastatic PCa xenografts derived from clinical specimens. The most highly up-
regulated transcript was LOC728606, a lncRNA now designated PCAT18. PCAT18 is 
specifically expressed in the prostate compared to 11 other normal tissues (p<0.05) 
and up-regulated in PCa compared to 15 other neoplasms (p<0.001). Cancer-specific 
up-regulation of PCAT18 was confirmed on an independent dataset of PCa and benign 
prostatic hyperplasia samples (p<0.001). PCAT18 was detectable in plasma samples 
and increased incrementally from healthy individuals to those with localized and 
metastatic PCa (p<0.01).  We identified a PCAT18-associated expression signature 
(PES), which is highly PCa-specific and activated in metastatic vs. primary PCa 
samples (p<1E-4, odds ratio>2). The PES was significantly associated with androgen 
receptor (AR) signalling. Accordingly, AR activation dramatically up-regulated PCAT18 
expression in vitro and in vivo. PCAT18 silencing significantly (p<0.001) inhibited 
PCa cell proliferation and triggered caspase 3/7 activation, with no effect on non-
neoplastic cells. PCAT18 silencing also inhibited PCa cell migration (p<0.01) and 
invasion (p<0.01). These results position PCAT18 as a potential therapeutic target 
and biomarker for metastatic PCa.
INTRODUCTION
The vast majority of prostate cancer (PCa)-related 
deaths are attributed to the progression from localized 
disease to metastatic castration-resistant PCa (mCRPC)
[1]. Despite tremendous research efforts, risk stratification 
of PCa patients at diagnosis is largely dependent on T 
stage, Gleason grade and plasma PSA levels, a method 
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that overlooks many potentially metastatic cases.  Even 
if aggressive cases are identified earlier, no curative 
therapeutic options are available for mCRPC[1, 2] and 
thus there is also a need to identify novel therapeutic 
targets.
Human transcriptome analysis has recently revealed 
that most transcribed RNAs are not translated and thus 
protein-coding genes account for a small percentage of all 
RNAs [3].  The non-coding transcripts include the well-
known ribosomal-, transfer- and micro-RNAs (rRNA, 
tRNA, miRNA respectively). MiRNA profiling in patient-
derived biological fluids is emerging as a powerful tool 
to differentiate localized and metastatic PCa [4]. Long 
non-coding RNAs (lncRNAs), transcripts longer than 
200bp with no protein-coding function [5],  represent a 
less investigated class of non-coding RNAs. Estimates 
suggest the number of human lncRNAs rivals that of 
protein-coding genes, ranging from 10,000 to 20,000  [6]. 
Despite these large numbers, only a handful of lncRNAs 
have been characterized.  Notably, most characterized 
lncRNAs display deregulated expression in cancer cells, 
where they  play oncogenic or tumor suppressive functions 
[6]. A striking feature of some lncRNAs is their tissue-
specificity, which prompted some authors to propose 
them as novel biomarkers and therapeutic targets [6, 7]. 
Two previously characterized lncRNAs (PCGEM1 and 
PCA3) are specifically expressed in PCa compared to an 
array of normal and neoplastic tissues [8, 9]. While the 
clinical utility of PCGEM1 has yet to be determined, 
PCA3 is present in urine samples from PCa patients and 
is able to detect the disease with 77.5% sensitivity and 
57.1% specificity [10]. For this reason, a PCA3 test has 
been approved by the Food and Drug Administration as 
a diagnostic tool. However, PCA3 levels are not able to 
discriminate between indolent and clinically aggressive 
PCa[10].  Functional data on PCA3 and PCGEM1 are still 
incomplete or are emerging in very recent publications 
[11-13], so it is not clear that either of them is a viable 
therapeutic target. 
Here, we describe a multi-step strategy to identify 
lncRNAs associated with PCa progression. First, we 
profiled lncRNA expression in a pair of non-metastatic/
metastatic patient-derived PCa xenografts. The most up-
regulated lncRNA was then queried in cancer databases 
and quantified in samples from localized PCa and mCRPC 
patients. Through this analysis, we identified a lncRNA 
(PCAT18) whose expression is: (1) significantly higher in 
PCa, compared to other benign and neoplastic tissues; (2) 
detectable in plasma samples and (3) able to discriminate 
between localized disease and mCRPC. Our functional 
analyses indicate that PCAT18 is androgen-regulated 
and a regulator of PCa cell proliferation, invasion, and 
migration, thereby positioning this gene as a putative 
therapeutic target.
RESULTS 
Transcriptomic profiling of paired patient-derived 
PCa xenografts
The identification of novel biomarkers and 
therapeutic targets for mCRPC has been hampered by 
the lack of suitable models that accurately reflect the 
clinical reality. This hurdle has been overcome by the 
generation of xenograft models developed from primary 
patient samples. In the present study we exploited 2 
PCa xenograft lines: LTL-313B and LTL-313H (www.
livingtumorlab.com). Both models were derived from 
primary PCa needle biopsies of the same patient, yet they 
display a strikingly different phenotype. LTL-313B cells 
showed little local invasion and no distant metastasis 
within 4 months post-engraftment, while LTL-313H 
xenografts  showed invasion into the mouse host kidney 
and distant metastases were consistently detectable in the 
hosts’ lungs within 3 months after engraftment (Fig. 1A). 
Both models show androgen-dependent PSA production 
and growth.
As the goal of this project was to identify 
previously uncharacterized lncRNAs associated with 
PCa metastasis, we performed RNA sequencing analysis 
on our patient-derived PCa xenografts using the strategy 
outlined in Suppl. Table. 1.  We found 153 up-regulated 
and 77 down-regulated lncRNAs in metastatic vs. non-
metastatic xenografts (Suppl. Table 2, 3). The vast 
majority of these transcripts have not been previously 
characterized. Of note, the list of up-regulated transcripts 
included two known oncogenic lncRNAs, H19 and 
PCGEM1 [9, 14], while the down-regulated transcripts 
included a well-known onco-suppressive lncRNA in PCa 
(PTENP1) [15].  PCA3 was detectable in both models, 
but its differential expression was below the significance 
threshold (LTL313H vs. LTL313B RPKM ratio=1.38). To 
validate our RNA sequencing data, we designed primers 
for 7 differentially modulated lncRNAs and confirmed 
greater than 2-fold up-regulation for each of them in the 
metastatic vs. non-metastatic xenografts (Fig.1B, primer 
sequences are listed in Suppl. Table 4).
Identification of PCAT18, a PCa-specific lncRNA
Among differentially expressed lncRNAs, the 
transcript with highest expression in the metastatic 
xenograft was LOC728606. This transcript showed a 
similar magnitude of fold-change with the oncogenic 
lncRNAs H19 and PCGEM1 (Fig.1B). LOC728606, 
flanked by AQP4 (Aquaporin-4) and KCTD1 (Potassium 
channel tetramerisation domain containing-1) loci, 
encodes for a 2598 bp RNA containing 2 exons (Fig.1C). 
Transcript length and sequence was confirmed by 
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comparative analysis of multiple clones (Suppl. Table 5). 
LOC728606 is classified as a “long intergenic non-coding 
RNA” based on the Ensembl algorithm (www.ensembl.
org). ORF Finder (www.ncbi.nlm.nih.gov/gorf/gorf.html) 
revealed that the transcript is composed of non-translatable 
regions for at least 84% of its length (Fig. 1D).Test-code 
software[16] confirmed that the RNA does not encode a 
protein (p<0.01), and PepBank [17] failed to identify any 
human peptide matching any ORF of this locus. 
To explore the clinical relevance of this gene, 
we investigated its expression in publically available 
databases and in human PCa samples. Albeit classical 
microarray platforms were restricted to mRNA detection, 
some of them might fortuitously hold probes matching 
a few lncRNAs [18]. We therefore mined LOC728606 
expression profiles on Oncomine and Gene Expression 
Omnibus (GEO) databases, which include large 
collections of microarray data from human samples[19, 
20]. Oncomine analysis revealed that LOC728606 is 
significantly up-regulated in PCa vs. normal tissues 
(Fig. 2A, Suppl. Table 6). To validate our findings, we 
measured by qPCR the expression levels of LOC728606 
in human prostate tissues (patients’ characteristics are 
summarized in Suppl. Table 7). This transcript was 
highly over-expressed (8.8-11.1 fold, p<0.001) in both 
low-Gleason and high-Gleason PCa samples, compared 
to benign prostatic hyperplasia (Fig. 2B). This suggests 
that its up-regulation is not merely the function of 
prostate cell hyper-proliferation. LOC728606 expression 
is significantly higher in normal prostate than in 11 other 
normal tissues (Fig. 2C). Moreover, this gene is over-
expressed in PCa compared to 15 other neoplastic tissues 
(Fig. 2D). Based on its cancer and tissue-specificity, we 
sought to determine if LOC728606 is detectable in plasma 
samples, and if it can be exploited as a biomarker for 
disease detection and monitoring, as suggested for other 
non-coding RNAs [4]. We therefore analyzed plasma 
samples from normal individuals, and those with localized 
PCa or mCRPC (n=25 per group, patients’ characteristics 
summarized in Suppl. Table 7).   Our results revealed a 
positive correlation between plasma LOC728606 levels 
and disease stage (Fig. 2E, p<0.01 for linear trend test), 
Figure1: A Hematoxylin-eosin staining of the xenograft (left panels) and mouse lung tissue (right panels) of transplantable 
prostate cancer tumor lines LTL-313H and LTL-313B. LTL-313H cells are more locally invasive to the adjacent kidney than -313B 
cells, and show signs of distant metastatic spreading (never found in LTL-313B-engrafted mice). .B, qPCR confirmation of RNA Seq. data 
(columns represent average value, bars represent standard deviation, 2 replicate experiments). Values indicate relative expression level in 
LTL-313H vs. LTL-313B cells. We chose the 4 most up-regulated and 3 randomly selected transcripts. C, Schematic representation of the 
PCAT18 locus (NLM “Gene” website). The gene is located in a region between 24,286 and 24,266 K (Chromosome 18 primary assembly). 
Lines represent introns, rectangles represent exons. Dotted lines represent a relative distance that is bigger than the one shown in the 
picture. Arrows represent transcription direction. The genes flanking PCAT18 locus (AQP4, aquaporin-4; KCTD1, Potassium Channel 
Tetramerization Domain-Containing Protein 1) are shown. D, ORF finder output for PCAT18 sequence. Open Reading Frames are shown 
as shaded squares throughout the sequence. Each lane represents a possible reading frame. The software identified no ORF longer than 267 
bp for a transcript longer than 2Kb. Considering 6 possible reading frames, protein-coding regions could account for no more than 16% of 
the whole transcript.
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with significantly higher levels in mCRPC compared to 
all other categories. To further strengthen our analysis, we 
confirmed the LOC728606 expression profile in both pre-
clinical and clinical samples, using a new set of primers 
and a different qPCR methodology (Suppl. Fig. 1 A, B). In 
light of these data, this gene was officially named PCAT18 
(Prostate Cancer-Associated Transcript-18) by the HUGO 
Gene Nomenclature Committee.
PCAT18 is an androgen-regulated gene
Based on its expression profile, we hypothesized that 
PCAT18 might contribute to PCa clinical characteristics 
and interact with known oncogenic pathways. Therefore, 
we performed significance analysis of microarray data 
(SAM) to identify PCAT18-associated transcripts. To this 
end, we exploited a dataset collecting RNA sequencing 
data and clinical information on 131 PCa samples and 
29 normal prostate tissues [21, 22]. Analysis of this large 
dataset further confirmed that PCAT18 is significantly 
(p<0.001) up-regulated in PCa vs. normal prostate 
(data not shown). SAM revealed 402 genes positively 
and significantly associated with PCAT18 expression 
(Suppl. Table 8). This PCAT18-associated expression 
signature (PES) was then uploaded into Oncomine to 
identify clinically meaningful associations and to perform 
pathway analysis (thresholds: p<E-4 odds ratio>2). PES 
was consistently up-regulated in PCa vs. normal tissue 
and PCa vs. other neoplasms in several cancer studies, 
Figure2: A, PCAT18 expression in normal prostate (n=6) and PCa (n=7) samples (horizontal bar represents median value, 
vertical bars represent minimum and maximum value per group). Query thresholds for all Oncomine analysis were p<0.01 and fold 
change>2. All Oncomine outputs passing these thresholds in prostate cancer studies are shown in Fig. 2. The non-significant correlations 
are summarized in Suppl. Table 6. Oncomine™ database (Compendia Bioscience, Ann Arbor, MI) was used for analysis and visualization. 
***p<0.001 (Oncomine Analysis).  Fold change: 7.2.  B, PCAT18 expression (qPCR) in benign prostatic hyperplasia (BPH, n=5), low-
Gleason (n=5) and high-Gleason (n=6) PCa samples. (Median-centered values, bars represent minimum and maximum value per group). 
***p<0.001 (ANOVA and Tukey’s post-test). C, Expression of PCAT18 in 12 benign tissues (GEO database, http://www.ncbi.nlm.nih.gov/
geo/, study ID: HG-U95D, n=2 per tissue, horizontal bar represents mean value, vertical bars represent minimum and maximum value per 
group). *p<0.05 compared to prostate (ANOVA and Holm-Sidak`s post-test). Fold Change: 2.78-8.75 (prostate compared to other tissues). 
D, Oncomine analyis of PCAT18 expression in 16 tumor tissues (median-centered values, bars represent minimum and maximum value per 
group). Data are centered to the median level of expression in the whole cohort. Sample size for each tumor type is in brackets: 1. Bladder 
Cancer (32); 2. Brain and CNS Cancer (4); 3. Breast Cancer (328); 4. Cervical Cancer (35); 5. Colorectal Cancer (330); 6. Esophageal 
Cancer (7);  7. Gastric Cancer (7);  8. Head and Neck Cancer (41);  9. Kidney Cancer (254);  10. Liver Cancer (11);  11. Lung Cancer (107); 
12. Lymphoma (19);  13. Ovarian Cancer (166);  14. Pancreatic Cancer (19);  15. Prostate Cancer (59);  16. Sarcoma (49). ***p<0.001 
E, PCAT18 expression (qPCR) in plasma samples from normal individuals and patients with localized or metastatic castration-resistant 
(mCRPC) PCa, (median-centered values, bars represent minimum and maximum value per group) **p<0.01  (ANOVA and Tukey’s post-
test). Samples were processed as previously described [4] for plasma separation, RNA extraction, retrotranscription and quantification. 
Oncomine™ (Compendia Bioscience, Ann Arbor, MI) was used for analysis and visualization.
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comprising more than 4000 human samples (Table 1). 
More interestingly, PES was significantly activated in 
metastatic vs. primary PCa samples. Pathway analysis 
revealed that PES is strongly associated with androgen 
receptor (AR) activation (Fig. 3A). 
 To gain insights into PCAT18 function, we 
performed in vitro studies on the metastatic PCa-derived 
LNCaP cell line[23]. In this model, dihydrotestosterone 
(DHT) treatment (24-48h) induced a more than 50-fold 
up-regulation of PCAT18 expression (Fig. 3B). In keeping 
with this relatively late up-regulation, we found no AR 
binding site in the PCAT18 putative promoter (Suppl. 
Table 9 and data from ChIP-on-chip[24]). This evidence 
suggests that AR indirectly activates PCAT18 expression. 
To experimentally determine whether PCAT18 is down-
regulated following androgen ablation, we assessed its 
expression following castration in two PCa xenograft 
models. The LTL331 model generates a typical androgen-
Figure 3: A, Transcripts positively associated with PCAT18 (SAM analysis, Q<0.5%) were analyzed in Oncomine for 
“literature defined concepts” (p<E-4, odds ratio>2). Here we show the top 3 concepts associated with JES. B, PCAT18 expression levels 
in untreated LNCaP cells (Control) and cells supplemented with dihydrotestosterone (DHT, 10nM, 6-24-48h). LNCaP cells were grown 
in phenol red-free medium (RPMI-1640) supplemented with 10% charcoal-stripped FBS. Columns represent mean value (2 independent 
experiments performed in triplicate), bars standard deviation. C, Expression of 3 genes in xenografts from mice supplemented with 
Testosterone (Test.) (2.5mg/mouse, n=2) or after castration (1, 2, 3 weeks, n=3). LOC728606 (PCAT18) down-regulation is comparable to 
that of PSA. Data are from LTL-331 human prostate cancer xenografts (www.livingtumorlab.com) and normalized to the average HPRT1 
expression level in testosterone-supplemented animals. HPRT1 expression is stable pre- and post-castration (unpublished microarray 
data). RNA extraction, retro-transcription and QPCR were performed as described in Fig. 1B legend. D, E, The living tumor lab (www.
livingtumorlab.com) comprises a collection of patient-derived PCa tumor tissue xenografts, originated with a method described in ref. An 
androgen-dependent PCa line (LTL313B) has been exposed to castrate-levels of testosterone for a prolonged time, in order to generate a 
castration-resistant subline. The figures show LTL313B tumor volume (C) and serum PSA levels (D) before and after castration. Neoplastic 
cells were implanted in male NOD/SCID intact mice, supplemented with testosterone until castration.  Serum PSA was measured and 
mice were sacrificed for tumor volume measurement at indicated time points, as described before[25].  At 12-16 weeks post-castration, 
a castration-resistant, AR-positive cell line was generated (LTL-313BR). F, PCAT18 expression was measured by qPCR in testosterone-
supplemented LTL313B, castrated xenografts (3 weeks) and in a CRPC subline (LTL313BR, no testosterone supplementation). 
Table 1: PCAT18-associated expression signature (PES) in prostate cancer samples. Genes positively associated 
with PCAT18 (SAM analysis Q<0.5%) were uploaded in the Oncomine databases (thresholds: p<E-4, odds ratio>2). 
The first column indicates the queried Oncomine concept. The second column (“Studies”) shows the number of 
independent studies showing up- or down-regulation of PES for a specific concept. Oncomine™ (Compendia 
Bioscience, Ann Arbor, MI) was used for analysis.
Concept Studies (Up/Down) P value Odds Ratio Total Samples
PCa vs. Normal 16/0 3.1E-116-1.7E-6 2.4-13.4 928
PCa vs. Other Neoplasms 4/0 3.1E-51-6.9E-7 2.5-6.8 3195
Metastatic  vs. Primary PCa 2/0 6.6E-8-2.3 E-5 2.9 27
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dependent PCa [25]. In this model, androgen deprivation 
induced a dramatic PCAT18 down-regulation (Fig. 3C). 
We then investigated the expression profile of PCAT18 in 
a recently developed CRPC subline (LTL313BR). When 
the LTL313B xenograft is exposed to castrate levels of 
androgens for several weeks, it reproducibly generates 
an AR+ CRPC subline (Fig. 3D, E) [25]. In this model, 
castration induced PCAT18 down-regulation, but the 
emergence of the CRPC subline was associated with 
PCAT18 up-regulation (Fig. 3F). 
Functional characterization of PCAT18
Our results to this point indicated that PCAT18 is 
a potential biomarker, is androgen-regulated, and may 
in turn regulate expression of numerous genes. We next 
set out to determine the functional relevance of PCAT18 
in PCa cells. To this aim, we measured its expression 
levels in a panel of prostate cell lines. In keeping with 
our previous data, PCAT18 expression was higher in AR-
positive than in AR-negative PCa cells (Suppl. Fig. 1C). 
Among AR-positive cells, PCAT18 levels incrementally 
increased from non-neoplastic (BPH1), to androgen-
sensitive (22Rv1, LNCaP) and androgen-insensitive 
(C4-2) PCa cells.  We therefore selected LNCaP and 
its castrate-resistant sub-line C4-2 [26] for lncRNA 
characterization and functional studies. RNA fractionation 
and quantification experiments revealed that PCAT18 is 
mainly located in the cytoplasm of PCa cells (Suppl. Fig. 
1 D). Indeed, the PCAT18 expression profile more similar 
to the protein-coding RNA GAPDH than to the nuclear-
retained lncRNA MALAT1 [27].
As a further step for PCAT18 characterization, we 
identified two PCAT18-specific siRNAs inducing greater 
than 80% gene knockdown at a 2nM concentration (Suppl. 
Fig. 1E) [28]. PCAT18 silencing (24-48h) significantly 
inhibited PCa cell invasion and migration (Fig. 4A, B). 
At later time points (5 days), PCAT18 silencing induced 
a significant growth inhibition in both LNCaP and C4-2 
cells (Fig. 4C, D), with no effect on non-neoplastic BPH1 
cells (Fig. 4E). Prolonged PCAT18 silencing (5 days) also 
triggered caspase 3/7 activation (Fig. 4F).
DISCUSSION 
PCa samples are often composed of multi-clonal 
subpopulations, each with a different mutational spectrum 
and metastatic potential[29]. Molecular analysis of 
PCa samples is therefore affected by this heterogeneity, 
which often masks the aggressive signature of truly 
metastatic cells. As a consequence, the development of 
Figure 4: A, C4-2 invasion was quantified 24h after the start of the invasion assay. Cells were transfected with 2nM Negative 
Control (NC) or PCATT18-targeting siRNA1 and siRNA2. Columns represent mean value (4 experiments) bar SD.  ***p<0.001 (ANOVA 
and Dunnett’s post-test). B , C4-2 cell migration was quantified at 6h, 24h or 48h post-transfection, **P<0.01, ***P<0.001 (siRNA vs. NC), 
2 way ANOVA and Tukey’s post-test.  C, D, E, MTT assay was performed on LNCaP (C) C4-2 (D) and BPH (E) cells treated with negative 
control (NC) or PCAT18-targeting siRNAs (both at 2nM concentration) on days 1-3-5 post-transfection, as previously described [30]. 
Dots represent mean value, lines standard deviation (2 experiments performed in triplicate, data normalized to cell number in NC-day1) 
***p<0.001 (2 way ANOVA and Tukey’s post-test). F, LNCaP cells were transfected with negative control (NC) or PCAT18-targeting 
siRNAs for 5 days. Bars represent mean values, lines standard deviations (2 independent experiments performed in triplicate). ***p<0.001 
with respect to NC (ANOVA and Dunnet’s post-test). 
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gene expression profile-based diagnostic and prognostic 
algorithms is particularly challenging in PCa. To address 
this concern, we analyzed the transcriptome of tumor 
tissue lines derived from two primary PCa biopsies of the 
same patient. When engrafted in the sub-renal capsule 
of immunocompromised mice, one tumor tissue line 
invariably generates non-metastatic and relatively non-
invasive tumors, while the other line is reproducibly able 
to generate highly invasive tumors, producing distant 
metastases through predictable routes. Since the two 
tumor tissue lines are derived from the same patient 
they represent the ideal model to study gene expression 
changes in PCa progression to a metastatic disease. A 
similar model has been successfully exploited for the 
identification of PCa-associated miRNAs and protein-
coding genes[30, 31].
The heuristic potential of our analysis is confirmed 
by the characterization of a lncRNA (PCAT18), whose 
function in human neoplasms had never been described 
before. Data from 4 independent datasets and more than 
600 human samples revealed that this gene is prostate-
specific and highly up-regulated in PCa. Even though 
the PCAT18 transcript has been reported before [32], its 
function and expression profile has not been previously 
described. Chinnaiyan and co-workers published a list 
of unannotated lncRNAs expressed in PCa [33]. Since 
they deliberately filtered out transcripts present in the 
RefSeq database they likely excluded PCAT18 from their 
analysis. More recently, Ren and co-workers published a 
list of lncRNAs expressed in PCa based on the fRNAdb 
database [34]. We actively searched for all the sequences 
matching PCAT18 in this database, finding that this locus 
is covered by just 4 short sequences that span <10% of 
the entire transcript. Moreover, we were not able to find 
the PCAT18-matching sequences in Ren’s list of PCa-
associated lncRNAs. Since Ren et al. only analyzed 
sequences longer than 200 bp. we assume they filtered 
out the short PCAT18-matching sequences present in the 
fRNAdb database. Our analysis, which identified putative 
lncRNAs based on the RefSeq database, thus complements 
the evidence accumulated by these 2 previous papers, 
thereby highlighting the importance of multiple analysis 
methods in the lncRNA field. The expression pattern of 
PCAT18 resembles that of PCA3 and PCGEM1. Our 
analysis indicates that PCAT18 is more over-expressed 
in PCa than PCGEM1 and that a set of patients over-
expressing this gene does not express PCA3 (data not 
shown). Thus our data suggest that PCAT18 can be a 
valuable addition to a multi-gene platform for use as a 
non-invasive method for PCa diagnosis. More importantly, 
since PCAT18 is so frequently over-expressed in PCa cells 
and is PCa-specific, we speculate that its measurement 
in plasma samples can allow earlier and more accurate 
detection of PCa progression to a metastatic and drug-
resistant stage. Indeed, identification of PCa-specific 
nucleotide sequences has been proposed as a tool to 
improve aggressive PCa detection[4]. Most of those 
studies were based on the measurement of PCa-associated 
genomic mutations or microRNAs. In this paper, we 
showed for the first time that a lncRNA detectable in 
plasma samples from PCa patients can discriminate 
between localized and mCRPC. 
Consistent with its prostate-specific expression 
profile, we found that PCAT18 up-regulation is triggered 
by AR activation (Fig 3). Our promoter analysis indicated 
that AR is unlikely to directly bind the PCAT18 promoter 
in keeping with our observations of a relatively late 
increase in PCAT18 expression following androgen 
exposure. In PCa cells, AR orchestrates regulatory 
networks through the activation of several transcription 
factors[35], some of which have putative binding sites in 
the PCAT18 promoter (Suppl. Table 9). For example, our 
RNA Seq. data indicate that c-FOS and PAX5 are highly 
up-regulated in LTL-313H vs. LTL313B cells (RPKM 
ratio>7, data not shown).  Thus, it is conceivable that 
AR activates another transcription factor, which in turn 
is directly responsible for PCAT18 up-regulation. This 
model is not in contrast with PCAT18’s high expression 
in mCRPC, as PCa progression to a castration-resistant 
phase still remains dependent on reactivation of this 
pathway[36]. Indeed, most of the recently approved 
therapies for mCRPC aim at targeting the AR pathway[1]. 
Our analyses indicate that PCAT18 is required for 
invasion, migration and proliferation of castration-
resistant PCa cells. The latter effect is probably triggered 
by the activation of caspase 3 and 7, which orchestrate 
the demolition phase of apoptosis[37]. Importantly, 
inhibition of PCAT18 had no effect on non-neoplastic 
cells. We believe these initial in vitro studies pave the 
way for development of novel therapeutic strategies (e. g. 
antisense oligonucleotides) to verify its function in vivo 
and ultimately be used as PCAT18-targeting drugs for the 
treatment of metastatic PCa. 
MATERIALS AND METHODS
Patient-derived xenografts.
Primary PCa biopsy specimens were collected at 
the BC Cancer Agency with the patient’s written informed 
consent.  The protocol for this procedure was approved by 
the University of British Columbia (UBC) Research Ethics 
Board (REB) (protocol number: H04-60131). NOD/SCID 
mice were bred and maintained at the British Columbia 
Cancer Research Centre Animal Facility (Vancouver, 
Canada). All experimental protocols were approved by the 
University of British Columbia Animal Care Committee 
(protocol number: A10-0100). Transplantable PCa tissue 
xenograft lines were established and maintained using 
subrenal capsule grafting as previously described [30]. 
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LTL313B and LTL313H tumor tissue cell lines were 
derived from 2 primary neoplasm biopsies obtained 
simultaneously from the same patient (total biopsies 
performed=8). At the time of biopsy, the donor was 
affected by treatment-naive prostate adenocarcinoma 
(Gleason Score=8) with signs of pelvic infiltration and 
bone metastasis. Immediately after pathological diagnosis, 
the patient received hormonal therapy, and 9 months after 
commencing treatment PSA reached a nadir 0.28ng/ml 
from a pre-treatment value of 19 ng/ml.
RNA Sequencing. 
Total RNA was extracted from LTL-313B and LTL-
313H primary xenografts, harvested on the same day, 
using Trizol (Invitrogen). RNA was sent to Otogenetics 
(Norcross, GA) for sequencing. Sequenced reads were 
aligned to the hg19 human genome assembly and 
contrasted to the transcriptome generated from all the 
spliced sequences annotated in the RefSeq database using 
the DNAnexus suite (www.dnanexus.com). Transcript 
level was quantified by calculating the RPKM (reads per 
kilobase of transcript per million mapped reads) value 
[38]. RPKM values were normalized to the root mean 
square (RMS) for each sample.  Mapped transcripts were 
annotated using the gene cards database (www.genecards.
org).  Genes were categorized as “protein coding” and 
“non-coding” based on their functional annotation. Among 
non-coding sequences rRNAs, tRNAs, miRNAs snoRNAs 
and other known classes of RNAs were excluded from 
further analysis. LncRNAs were defined as all non-coding 
sequences longer than 200 bp and not belonging to other 
RNA categories. Based on those filtering criteria, we 
identified 1653 lncRNAs expressed in PCa xenografts.
Quantification of lncRNA expression levels.
Primers targeting selected lncRNAs were designed 
using BLAST software. Primer sequences, listed in 
Suppl. Table 2, were contrasted to the Homo Sapiens and 
Mus Musculus trancriptome to ensure their specificity 
for the intended target gene. Custom DNA oligos were 
provided by Invitrogen.  RNA was extracted by RNAeasy 
kit (Qiagen) and retro transcribed by QuantiTect kit 
(Qiagen). The QuantiTect kit includes a genomic DNA 
elimination step, which was always carefully performed 
for the experiments presented in this paper. Quantitative 
PCR was performed as previously described [31] using 
cDNA, primers and KAPA SYBR fast Universal Master 
Mix through ABIPrism 7900HT (Applied Biosystems) 
and following manufacturers’ instructions. We used 
the 2-ΔΔCT method for calculating the fold changes 
relative to endogenous controls (HPRT and GAPDH, 
whose expression was stable in primary and metastatic 
xenografts, according to RNA Seq. data).  We were not 
able to design effective primers for LOC100329109 (a 
pseudogene).  We designed primers specific for the 2 main 
variants of linc461 (transcript variant 1 LINC461_1 and 
transcript variant 3 LINC461_3) to confirm separately 
their up-regulation.
To confirm PCAT18 expression patterns with 
another methodology, we employed Applied Biyosystem 
Non-coding RNA assay Hs03669364_m1, which is 
specific for LOC728606 (PCAT18) and spans the exon1-
exon2 boundary. QPCR was performed according to 
manufacturer`s instructions on the ABIPrism 7900HT 
(Applied Biosystems). We used the 2-ΔΔCT method for 
calculating the fold changes relative to endogenous control 
(GAPDH).
TaqMan qPCR was also performed to quantify 
the sub-cellular localization of PCAT18. GAPDH and 
MALAT1 (Hs00273907_s1). Total, cytoplasmic and 
nuclear RNA was extracted and purified using the Ambion 
PARIS kit (Life Technologies), following manufacturer`s 
instruction.  
In vitro experiments.
Unless otherwise specified, Prostate cancer- and 
benign prostatic hyperplasia-derived cell lines were 
maintained in 10% fetal bovine serum (GIBCO, Life 
Technologies ) and RPMI 1640  growth medium (GIBCO, 
Life Technologies). 
Gene Silencing: cells were treated with 2nM 
PCAT18 (LOC728606)-targeting siRNAs (siRNA1 and 
siRNA2) or negative control (NC) reagent (Dicer substrate 
siRNAs, Integrated DNA Technology, Duplex names: 
NR_024259_1; NR_024259_2;  DS_NC1), following 
manufacturer`s instructions. NC (negative transfection 
control) is a DsiRNA duplex that does not target any 
known human or mouse transcript.  Lipofectamine 
RNAiMaX (Invitrogen) was employed as the transfection 
reagent. RNA extraction, retro-transcription and qPCR 
were performed as described in Fig. 1B legend. 
MTT assay was performed on LNCaP C4-2 
and BPH cells treated with NC or PCAT18-targeting 
siRNAs (both at 2nM concentration) on days 1-3-5 post-
transfection, as previously described [30].
Caspase 3 and 7 activity was quantified through 
Caspase-Glo 3/7 assay (Promega), as previously described 
[39] on cells transfected with the above described protocol. 
The wound healing assay was performed in triplicate 
on C4-2 cells  as  previously described [24]. Transfection 
protocols were identical to those described above.  12 
hours post-transfection, a `wound` was produced using a 
P20 pipette tip. Pictures were taken at marked spots 0-6-
24-48h post-wounding, using a Zeiss Axiovert 40 CFL 
inverted microscope connected to Axiovision 4.7 software.
Invasion assay was performed in triplicate on C4-2 
cells using BD BioCoat™ BD MatrigelTM Invasion 
Chambers (24-well plates) and following manufacturer’s 
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instructions. Transfection was performed on day 0, 
as described above. After 12 hours, cells were plated 
in the invasion chambers. 16 hours post-plating, we 
followed a previously described method for analysis and 
quantification of invading cells [40]. 
Patient datasets.
Prostate tissue samples: Samples from patients with 
benign prostatic hyperplasia (BPH) or PCa were collected 
at the Stephanshorn Clinic in St. Gallen Switzerland, after 
study protocol approval by the local ethical committee 
(protocol number: ZeTuP19/04). Resected specimens 
were immediately transferred on ice to the Institute 
for Pathology of the Kantons Hospital, St.Gallen for 
examination. Small tissue samples from macroscopically 
visible tumor and non-tumor prostate tissue were dissected, 
snap frozen in liquid nitrogen and cryo-preserved at –80 
°C. Samples were cut in a cryo-microtome and a slide 
of each probe was stained with hematoxylin-eosin for 
histological verification. RNA was isolated from frozen 
materials using the TRI-reagent (Ambion) method 
according to the manufacturer’s guidelines. cDNA was 
synthesized from 1μg of total RNA using Superscript II 
RNase H-reverse transcriptase (Invitrogen).
Plasma Samples: Upon study protocol approval 
by UBC REB (protocol number: H11-00525), and 
after obtaining written informed consent from study 
participants, blood samples and clinico-pathological 
data were collected at the British Columbia Cancer 
Agency (BCCA), Vancouver Centre. Three cohorts 
were evaluated: 25 individuals with no clinical sign of 
neoplasm; 25 PCa patients with treatment-naïve localized 
disease (Localized PCa); 25 patients with clinically 
confirmed metastatic PCa and progressive disease despite 
castration therapy (mCRPC). Risk groups are defined 
based on pre-prostatectomy serum PSA value, T stage 
and Gleason Grade, as recommended by Genito-Urinary 
Radiation Oncologists of Canada [2]. PCa diagnosis was 
confirmed by pathological examination of tumor biopsies 
for each enrolled patient. Localized PCa cases were 
defined as those with no pathological evidence of lymph 
node dissemination and no clinical evidence of metastatic 
diffusion. PSA measurement and RNA extraction were 
performed on samples collected before prostatectomy and 
on treatment-naive patients. Metastatic cases were defined 
as those having clinical or pathological evidence of cancer 
dissemination to any of the following: lymph nodes, bones 
or soft tissues (lung, brain, spine, testis). 
LOC728606 expression was also queried in 
Oncomine (www.oncomine.com) GEO (www.ncbi.nlm.
nih.gov/geo/) and Cbio portal (www.cbioportal.org) gene 
expression databases. Analysis was restricted to PCa  and 
prostate-derived samples. 
Significance Analysis of Microarrays (SAM) was 
performed in R using the 20 PCa samples expressing the 
highest and lowest levels of PCAT18 from Cbio database 
[21] prostate cancer samples [22]. Transcripts positively 
associated with PCAT18 (with Q<0.5%) were uploaded 
to the Oncomine database to investigate correlations with 
clinical variables (threshold: p<E-4, odds ratio>2). 
Statistcal analyses.
Unless otherwise specified, experiments were 
repeated at least twice and data were presented and 
analyzed through GraphPad Prism 6 software.
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